Kite Pharma Inc. (KITE): NHS Analysis Determines a £530K Price Tag Reasonable for CAR T Therapy

Kite Pharma Inc. (KITE): NHS Analysis Determines a £530K Price Tag Reasonable for CAR T Therapy

The study was conducted for young ALL and determined a price of £530K ($649K) was justified

Healthcare

Canaccord on Kite Pharma Inc (KITE)

Canaccord believes the CAR-19 data suggest that KTE-C19 is a favorable option for NHL patients with few, if any, other treatment options, which may provide long-term potentially curative benefit

Jefferies on Gilead Sciences, Inc. (NASDAQ:GILD)

U.S. sales for 1Q17 look to be tracking in line with Jefferies' $800M estimate and $790M consensus

Ackman's Exit Sends Valeant Pharmaceuticals Intl Inc (VRX) Shares to Greater Than 7-Year Low

Valeant Pharmaceuticals’ recent loss of Bill Ackman’s investment serves as a point of caution for the investors going forward

Jefferies on Biotechnology: Celgene Corporation (NASDAQ:CELG)

The results were favorable for the up and coming drug with a differentiated MOA

Valeant Pharmaceuticals Intl Inc (VRX) Considering of Pershing's Efforts to Create a Turnaround Situation

Considering all of Pershing's efforts to create a turnaround situation with the new management team, BMO Capital Markets believes this "throwing in the towel" at these levels sends a poor signal regarding the road ahead for Valeant

Valeant Pharmaceuticals International, Inc. (NYSE:VRX): Pershing Square Sells Final Stake For Large Tax Loss

Valeant's shares fell about 10% during aftermarket hours yesterday as Pershing Square sells its final stake in the business